相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
Ghassan K. Abou-Alfa et al.
ONCOLOGIST (2019)
Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
Robert A. Burger et al.
GYNECOLOGIC ONCOLOGY (2018)
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2017)
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Toni K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Phase 2 Study of Dalantercept, an Activin Receptor-Like Kinase-1 Ligand Trap, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Antonio Jimeno et al.
CANCER (2016)
Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
LANCET ONCOLOGY (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer
Sara I. Cunha et al.
CANCER RESEARCH (2015)
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: A An NRG Oncology/Gynecologic Oncology Group Study 0229N
Vicky Makker et al.
GYNECOLOGIC ONCOLOGY (2015)
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2015)
International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
Jenny J. Ko et al.
LANCET ONCOLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor-like Kinase-1 Ligand Trap, in Patients with Advanced Cancer
Johanna C. Bendell et al.
CLINICAL CANCER RESEARCH (2014)
Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?
Rupal S. Bhatt et al.
CLINICAL CANCER RESEARCH (2014)
Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2013)
Phase 1 Trial of Everolimus Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Ana M. Molina et al.
CANCER (2012)
Tumor Lymphangiogenesis as a Potential Therapeutic Target
Tam Duong et al.
JOURNAL OF ONCOLOGY (2012)
ALK1 as an emerging target for antiangiogenic therapy of cancer
Sara I. Cunha et al.
BLOOD (2011)
Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
Dana D. Hu-Lowe et al.
CANCER RESEARCH (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Sylvie Negrier et al.
LANCET ONCOLOGY (2011)
Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Darren R. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling
T Seki et al.
CIRCULATION RESEARCH (2003)
Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis
SP Oh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
